Evercore ISI Has Lowered Expectations for Cardlytics (NASDAQ:CDLX) Stock Price

Cardlytics (NASDAQ:CDLX) had its price target decreased by Evercore ISI from $4.00 to $3.00 in a research report sent to investors on Thursday,Benzinga reports. Evercore ISI currently has an in-line rating on the stock.

Separately, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Thursday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Cardlytics presently has a consensus rating of “Hold” and a consensus price target of $6.42.

Cardlytics Trading Up 19.3 %

Shares of CDLX stock opened at $2.47 on Thursday. Cardlytics has a 12-month low of $1.77 and a 12-month high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm’s 50 day moving average is $3.00 and its 200 day moving average is $3.49. The stock has a market capitalization of $125.53 million, a P/E ratio of -0.40 and a beta of 1.62.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 46,857 shares of Cardlytics stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total value of $159,313.80. Following the sale, the chief executive officer now directly owns 418,637 shares in the company, valued at approximately $1,423,365.80. The trade was a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alexis Desieno sold 24,778 shares of Cardlytics stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the sale, the chief financial officer now owns 140,948 shares in the company, valued at approximately $479,223.20. This represents a 14.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 111,454 shares of company stock worth $391,864. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors and hedge funds have recently made changes to their positions in CDLX. Atom Investors LP purchased a new position in shares of Cardlytics during the 3rd quarter worth about $33,000. Tallon Kerry Patrick bought a new stake in shares of Cardlytics in the 4th quarter valued at about $37,000. ProShare Advisors LLC bought a new stake in shares of Cardlytics in the 4th quarter valued at about $43,000. Intech Investment Management LLC bought a new position in shares of Cardlytics during the 3rd quarter worth approximately $47,000. Finally, Virtu Financial LLC bought a new position in shares of Cardlytics during the 4th quarter worth approximately $62,000. 68.10% of the stock is owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.